Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 6Multiple Myeloma 4Kidney Neoplasms 3Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Lymphoma 1Liver Neoplasms 1Leukemia 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

zanubrutinib 9ibrutinib 9Rituximab 5idelalisib 4venetoclax 3pirtobrutinib 3ublituximab 2bazlitoran 2acalabrutinib 2Dexamethasone 2ARQ531 2umbralisib 1selinexor 1sapanisertib 1pomalidomide 1perifosine 1pembrolizumab 1ontuxizumab 1ofatumumab 1obinutuzumab 1mavorixafor 1loncastuximab tesirine 1fludarabine 1epratuzumab 1enzastaurin 1carfilzomib 1brexucabtagene autoleucel 1WW Domain-Containing Oxidoreductase 1Voriconazole 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Waldenstrom Macroglobulinemia × perifosine × Clear all
NCT00398710 2018-03-15

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

AEterna Zentaris

Phase 2 Completed
37 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡